Catalyst Dossier · compiled by CeliA 🧫

TENAX THERAPEUTICS, INC. (TENX)

Pharmaceutical Preparations · market cap $318M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-12

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-12Earningsimp 5/10
2026-10-15 (est.)Phase 3 · TNX-103imp 9/10

Pipeline

Asset	Phase	Indication
Levosimendan	Phase 2	Hypertension Pulmonary Secondary
perfluorocarbon emulsion (Oxycyte) infusion	Phase 2	Traumatic Brain Injury
Levosimendan 2.5 mg/ml Injectable Solution	Phase 2	Hypertension Pulmonary Secondary Heart Failure
TNX-103	Phase 3	Pulmonary Hypertension

Price & technical context

3-month

-3.4%

6-month

+28.8%

12-month

+168.9%

52-wk range

$5.74–$18.27

vs 50-day MA

+25.3%

vs 200-day MA

+35.8%

Realized vol

70.4%

Max drawdown

-42.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TENX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.